🇺🇸 ESPO in United States

79 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 12 reports (15.19%)
  2. Pyrexia — 12 reports (15.19%)
  3. Condition Aggravated — 8 reports (10.13%)
  4. Haemodialysis — 8 reports (10.13%)
  5. Renal Impairment — 8 reports (10.13%)
  6. Blood Creatinine Increased — 7 reports (8.86%)
  7. Cerebral Haemorrhage — 6 reports (7.59%)
  8. Haemoglobin Decreased — 6 reports (7.59%)
  9. Hypertension — 6 reports (7.59%)
  10. Nausea — 6 reports (7.59%)

Source database →

ESPO in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ESPO approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ESPO in United States?

Jiangsu Hansoh Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.